Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life
Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) st...
Saved in:
Published in | Radiation oncology (London, England) Vol. 12; no. 1; p. 53 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central
14.03.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) study was conducted to investigate correlations between radiation - induced DNA damage biomarker levels, and acute and late bowel, urinary, and sexual toxicity.
Twelve patients treated with
I PPB monotherapy (145Gy) for prostate cancer were included in this prospective study. Post-implant CT based dosimetry assessed the minimum dose encompassing 90% (D
) of the whole prostate volume (global), sub-regions of the prostate (12 sectors) and the near maximum doses (D
, D
) for the rectum and bladder. Six blood samples were collected from each patient; pre-treatment, 1 h (h), 4 h, 24 h post-implant, at 4 weeks (w) and at 3 months (m). DNA double strand breaks were investigated by staining the blood samples with immunofluorescence antibodies to γH2AX and 53BP1 proteins (γH2AX/53BP1). Patient self-scored quality of life from the Expanded Prostate Cancer Index Composite (EPIC) were obtained at baseline, 1 m, 3 m, 6 m, 9 m, 1 year (y), 2y and 3y post-treatment. Spearman's correlation coefficients were used to evaluate correlations between temporal changes in γH2AX/53BP1, dose and toxicity.
The minimum follow up was 2 years. Population mean prostate D
was 144.6 ± 12.1 Gy and rectal near maximum dose D
= 153.0 ± 30.8 Gy and D
= 62.7 ± 12.1 Gy and for the bladder D
= 123.1 ± 27.0 Gy and D
= 70.9 ± 11.9 Gy. Changes in EPIC scores from baseline showed high positive correlation between acute toxicity and late toxicity for both urinary and bowel symptoms. Increased production of γH2AX/53BP1 at 24 h relative to baseline positively correlated with late bowel symptoms. Overall, no correlations were observed between dose metrics (prostate global or sector doses) and γH2AX/53BP1 foci counts.
Our results show that a prompt increase in γH2AX/53BP1foci at 24 h post-implant relative to baseline may be a useful measure to assess elevated risk of late RT - related toxicities for PPB patients. A subsequent investigation recruiting a larger cohort of patients is warranted to verify our findings. |
---|---|
AbstractList | Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) study was conducted to investigate correlations between radiation - induced DNA damage biomarker levels, and acute and late bowel, urinary, and sexual toxicity.
Twelve patients treated with
I PPB monotherapy (145Gy) for prostate cancer were included in this prospective study. Post-implant CT based dosimetry assessed the minimum dose encompassing 90% (D
) of the whole prostate volume (global), sub-regions of the prostate (12 sectors) and the near maximum doses (D
, D
) for the rectum and bladder. Six blood samples were collected from each patient; pre-treatment, 1 h (h), 4 h, 24 h post-implant, at 4 weeks (w) and at 3 months (m). DNA double strand breaks were investigated by staining the blood samples with immunofluorescence antibodies to γH2AX and 53BP1 proteins (γH2AX/53BP1). Patient self-scored quality of life from the Expanded Prostate Cancer Index Composite (EPIC) were obtained at baseline, 1 m, 3 m, 6 m, 9 m, 1 year (y), 2y and 3y post-treatment. Spearman's correlation coefficients were used to evaluate correlations between temporal changes in γH2AX/53BP1, dose and toxicity.
The minimum follow up was 2 years. Population mean prostate D
was 144.6 ± 12.1 Gy and rectal near maximum dose D
= 153.0 ± 30.8 Gy and D
= 62.7 ± 12.1 Gy and for the bladder D
= 123.1 ± 27.0 Gy and D
= 70.9 ± 11.9 Gy. Changes in EPIC scores from baseline showed high positive correlation between acute toxicity and late toxicity for both urinary and bowel symptoms. Increased production of γH2AX/53BP1 at 24 h relative to baseline positively correlated with late bowel symptoms. Overall, no correlations were observed between dose metrics (prostate global or sector doses) and γH2AX/53BP1 foci counts.
Our results show that a prompt increase in γH2AX/53BP1foci at 24 h post-implant relative to baseline may be a useful measure to assess elevated risk of late RT - related toxicities for PPB patients. A subsequent investigation recruiting a larger cohort of patients is warranted to verify our findings. Background Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) study was conducted to investigate correlations between radiation - induced DNA damage biomarker levels, and acute and late bowel, urinary, and sexual toxicity. Methods Twelve patients treated with 125I PPB monotherapy (145Gy) for prostate cancer were included in this prospective study. Post-implant CT based dosimetry assessed the minimum dose encompassing 90% (D90%) of the whole prostate volume (global), sub-regions of the prostate (12 sectors) and the near maximum doses (D0.1cc, D2cc) for the rectum and bladder. Six blood samples were collected from each patient; pre-treatment, 1 h (h), 4 h, 24 h post-implant, at 4 weeks (w) and at 3 months (m). DNA double strand breaks were investigated by staining the blood samples with immunofluorescence antibodies to gamma H2AX and 53BP1 proteins ( gamma H2AX/53BP1). Patient self-scored quality of life from the Expanded Prostate Cancer Index Composite (EPIC) were obtained at baseline, 1 m, 3 m, 6 m, 9 m, 1 year (y), 2y and 3y post-treatment. Spearman's correlation coefficients were used to evaluate correlations between temporal changes in gamma H2AX/53BP1, dose and toxicity. Results The minimum follow up was 2 years. Population mean prostate D90% was 144.6 plus or minus 12.1 Gy and rectal near maximum dose D0.1cc = 153.0 plus or minus 30.8 Gy and D2cc = 62.7 plus or minus 12.1 Gy and for the bladder D0.1cc = 123.1 plus or minus 27.0 Gy and D2cc = 70.9 plus or minus 11.9 Gy. Changes in EPIC scores from baseline showed high positive correlation between acute toxicity and late toxicity for both urinary and bowel symptoms. Increased production of gamma H2AX/53BP1 at 24 h relative to baseline positively correlated with late bowel symptoms. Overall, no correlations were observed between dose metrics (prostate global or sector doses) and gamma H2AX/53BP1 foci counts. Conclusions Our results show that a prompt increase in gamma H2AX/53BP1foci at 24 h post-implant relative to baseline may be a useful measure to assess elevated risk of late RT - related toxicities for PPB patients. A subsequent investigation recruiting a larger cohort of patients is warranted to verify our findings. Background Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) study was conducted to investigate correlations between radiation − induced DNA damage biomarker levels, and acute and late bowel, urinary, and sexual toxicity. Methods Twelve patients treated with 125I PPB monotherapy (145Gy) for prostate cancer were included in this prospective study. Post-implant CT based dosimetry assessed the minimum dose encompassing 90% (D90%) of the whole prostate volume (global), sub-regions of the prostate (12 sectors) and the near maximum doses (D0.1cc, D2cc) for the rectum and bladder. Six blood samples were collected from each patient; pre-treatment, 1 h (h), 4 h, 24 h post-implant, at 4 weeks (w) and at 3 months (m). DNA double strand breaks were investigated by staining the blood samples with immunofluorescence antibodies to γH2AX and 53BP1 proteins (γH2AX/53BP1). Patient self-scored quality of life from the Expanded Prostate Cancer Index Composite (EPIC) were obtained at baseline, 1 m, 3 m, 6 m, 9 m, 1 year (y), 2y and 3y post-treatment. Spearman’s correlation coefficients were used to evaluate correlations between temporal changes in γH2AX/53BP1, dose and toxicity. Results The minimum follow up was 2 years. Population mean prostate D90% was 144.6 ± 12.1 Gy and rectal near maximum dose D0.1cc = 153.0 ± 30.8 Gy and D2cc = 62.7 ± 12.1 Gy and for the bladder D0.1cc = 123.1 ± 27.0 Gy and D2cc = 70.9 ± 11.9 Gy. Changes in EPIC scores from baseline showed high positive correlation between acute toxicity and late toxicity for both urinary and bowel symptoms. Increased production of γH2AX/53BP1 at 24 h relative to baseline positively correlated with late bowel symptoms. Overall, no correlations were observed between dose metrics (prostate global or sector doses) and γH2AX/53BP1 foci counts. Conclusions Our results show that a prompt increase in γH2AX/53BP1foci at 24 h post-implant relative to baseline may be a useful measure to assess elevated risk of late RT − related toxicities for PPB patients. A subsequent investigation recruiting a larger cohort of patients is warranted to verify our findings. BACKGROUNDLow-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) study was conducted to investigate correlations between radiation - induced DNA damage biomarker levels, and acute and late bowel, urinary, and sexual toxicity. METHODSTwelve patients treated with 125I PPB monotherapy (145Gy) for prostate cancer were included in this prospective study. Post-implant CT based dosimetry assessed the minimum dose encompassing 90% (D90%) of the whole prostate volume (global), sub-regions of the prostate (12 sectors) and the near maximum doses (D0.1cc, D2cc) for the rectum and bladder. Six blood samples were collected from each patient; pre-treatment, 1 h (h), 4 h, 24 h post-implant, at 4 weeks (w) and at 3 months (m). DNA double strand breaks were investigated by staining the blood samples with immunofluorescence antibodies to γH2AX and 53BP1 proteins (γH2AX/53BP1). Patient self-scored quality of life from the Expanded Prostate Cancer Index Composite (EPIC) were obtained at baseline, 1 m, 3 m, 6 m, 9 m, 1 year (y), 2y and 3y post-treatment. Spearman's correlation coefficients were used to evaluate correlations between temporal changes in γH2AX/53BP1, dose and toxicity. RESULTSThe minimum follow up was 2 years. Population mean prostate D90% was 144.6 ± 12.1 Gy and rectal near maximum dose D0.1cc = 153.0 ± 30.8 Gy and D2cc = 62.7 ± 12.1 Gy and for the bladder D0.1cc = 123.1 ± 27.0 Gy and D2cc = 70.9 ± 11.9 Gy. Changes in EPIC scores from baseline showed high positive correlation between acute toxicity and late toxicity for both urinary and bowel symptoms. Increased production of γH2AX/53BP1 at 24 h relative to baseline positively correlated with late bowel symptoms. Overall, no correlations were observed between dose metrics (prostate global or sector doses) and γH2AX/53BP1 foci counts. CONCLUSIONSOur results show that a prompt increase in γH2AX/53BP1foci at 24 h post-implant relative to baseline may be a useful measure to assess elevated risk of late RT - related toxicities for PPB patients. A subsequent investigation recruiting a larger cohort of patients is warranted to verify our findings. |
ArticleNumber | 53 |
Author | Prise, Kevin M Lyons, Ciara A Brady, Darren Jain, Suneil Horn, Simon Hounsell, Alan R O'Sullivan, Joe M Osman, Sarah O S McGarry, Conor K Crowther, Karen McMahon, Stephen J Yoosuf, Ahamed B Mohamed Mitchell, Darren |
Author_xml | – sequence: 1 givenname: Sarah O S surname: Osman fullname: Osman, Sarah O S email: s.osman@qub.ac.uk organization: Centre of Cancer Research and Cell Biology, Queen's University Belfast, BT7 1NN, Belfast, UK. s.osman@qub.ac.uk – sequence: 2 givenname: Simon surname: Horn fullname: Horn, Simon organization: Centre of Cancer Research and Cell Biology, Queen's University Belfast, BT7 1NN, Belfast, UK – sequence: 3 givenname: Darren surname: Brady fullname: Brady, Darren organization: Centre of Cancer Research and Cell Biology, Queen's University Belfast, BT7 1NN, Belfast, UK – sequence: 4 givenname: Stephen J surname: McMahon fullname: McMahon, Stephen J organization: Centre of Cancer Research and Cell Biology, Queen's University Belfast, BT7 1NN, Belfast, UK – sequence: 5 givenname: Ahamed B Mohamed surname: Yoosuf fullname: Yoosuf, Ahamed B Mohamed organization: Radiotherapy Physics, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK – sequence: 6 givenname: Darren surname: Mitchell fullname: Mitchell, Darren organization: Clinical Oncology, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK – sequence: 7 givenname: Karen surname: Crowther fullname: Crowther, Karen organization: Radiotherapy Physics, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK – sequence: 8 givenname: Ciara A surname: Lyons fullname: Lyons, Ciara A organization: Centre of Cancer Research and Cell Biology, Queen's University Belfast, BT7 1NN, Belfast, UK – sequence: 9 givenname: Alan R surname: Hounsell fullname: Hounsell, Alan R organization: Radiotherapy Physics, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK – sequence: 10 givenname: Kevin M surname: Prise fullname: Prise, Kevin M organization: Centre of Cancer Research and Cell Biology, Queen's University Belfast, BT7 1NN, Belfast, UK – sequence: 11 givenname: Conor K surname: McGarry fullname: McGarry, Conor K organization: Radiotherapy Physics, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK – sequence: 12 givenname: Suneil surname: Jain fullname: Jain, Suneil organization: Clinical Oncology, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK – sequence: 13 givenname: Joe M surname: O'Sullivan fullname: O'Sullivan, Joe M organization: Clinical Oncology, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28288658$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUuLFDEUhYOMOA_9AW4k4MZNaW4enRSCMAzjAwZ0MQt3IVW5sWusrnQnKbX-_aTtcRhduQjJJd85nOSckqMpTkjIc2CvAczqTQbBQDYMdMN0yxt4RE5AS9No0F-PHpyPyWnON4xJJVj7hBxzw41ZKXNCdl9SzMUVpL2beky0JKyTpz-HsqZdcv16KWtMbru8pW6i-Gs7xuRKTAvNZfYLjYH6mLHxuMXJ41RoN8SNS98x5arwdDe7cSi_wXEI-JQ8Dm7M-OxuPyPX7y-vLz42V58_fLo4v2p6uWKlCRq1BK0kmN4rExTnnrdGhKBCayRKYbhSxnjRKuChM4LrVnYdOAadWokz8u5gu527Dfq-BktutNs01GyLjW6wf99Mw9p-iz-sEtLoVlWDV3cGKe5mzMVuhtzjOLoJ45wtmBaM2q__QLVWXFXTir78B72Jc5rqR1TKSCMqt6fgQPW1nZww3OcGZvfV20P1tlZv99VbqJoXDx98r_jTtbgFs6is8w |
CitedBy_id | crossref_primary_10_1016_j_ctrv_2018_03_005 crossref_primary_10_1016_j_ijrobp_2023_02_054 crossref_primary_10_1016_j_semradonc_2019_09_001 crossref_primary_10_1007_s00261_023_03905_1 crossref_primary_10_3390_cancers14133058 |
Cites_doi | 10.1001/jama.280.11.969 10.1667/RR13342.1 10.1016/j.radonc.2007.01.014 10.1118/1.3246613 10.1148/radiol.2421060171 10.1016/j.ijrobp.2007.12.052 10.1016/j.ijrobp.2013.11.219 10.1056/NEJMoa074311 10.1118/1.1646040 10.1007/s00259-015-3083-9 10.1164/ajrccm/136.5.1213 10.1016/j.brachy.2012.08.007 10.1200/JCO.2005.07.116 10.1182/blood.V91.5.1653 10.1118/1.598058 10.1016/S0090-4295(00)00858-X 10.1016/S0895-4356(00)00314-0 10.3389/fonc.2012.00058 10.1016/j.dnarep.2013.07.002 10.1097/01.ju.0000154633.73092.8e 10.1016/j.brachy.2015.05.009 10.1371/journal.pone.0025113 10.1016/0167-5699(96)80547-0 10.1016/S0140-6736(02)09408-4 10.1200/JCO.2014.55.1192 10.1186/2193-1801-3-329 10.1074/jbc.273.10.5858 10.2967/jnumed.115.164814 10.5114/jcb.2012.29363 10.1016/S0302-2838(02)00018-0 10.1016/j.ijrobp.2014.06.031 10.1016/j.ijrobp.2012.06.041 10.1016/j.radonc.2011.05.071 10.1016/j.radonc.2015.01.005 10.1073/pnas.1002213107 10.1016/S0360-3016(97)00221-6 10.1093/jrr/rru096 10.2967/jnumed.109.071357 10.1667/RR13911.1 10.1016/j.ijrobp.2005.08.016 10.1186/1748-717X-6-62 |
ContentType | Journal Article |
Copyright | Copyright BioMed Central 2017 The Author(s). 2017 |
Copyright_xml | – notice: Copyright BioMed Central 2017 – notice: The Author(s). 2017 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QO 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH K9. M0S M1P P64 PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1186/s13014-017-0792-1 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Biotechnology Research Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biotechnology and BioEngineering Abstracts Access via ProQuest (Open Access) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Technology Research Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library Biotechnology Research Abstracts ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Engineering Research Database ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Engineering Research Database Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1748-717X |
EndPage | 53 |
ExternalDocumentID | 10_1186_s13014_017_0792_1 28288658 |
Genre | Journal Article |
GeographicLocations | United Kingdom--UK |
GeographicLocations_xml | – name: United Kingdom--UK |
GrantInformation_xml | – fundername: ; grantid: CE013-2-004 |
GroupedDBID | --- -A0 0R~ 123 29P 2WC 3V. 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK E3Z EBD EBLON EBS ECM EIF EJD ESX F5P FYUFA GROUPED_DOAJ H13 HMCUK HYE I-F IAO IHR INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TUS UKHRP WOQ WOW ~8M AAYXX CITATION 7QO 7XB 8FD 8FK AZQEC DWQXO FR3 K9. P64 PQEST PQUKI PRINS 7X8 AFGXO 5PM |
ID | FETCH-LOGICAL-c460t-f7e74175418cd58f522d2983ff5f984e43825588d39512fb832794bb1a01b563 |
IEDL.DBID | RPM |
ISSN | 1748-717X |
IngestDate | Tue Sep 17 21:26:17 EDT 2024 Fri Aug 16 08:02:47 EDT 2024 Fri Aug 16 21:39:57 EDT 2024 Fri Aug 30 23:58:05 EDT 2024 Thu Sep 12 17:03:46 EDT 2024 Sat Sep 28 08:35:39 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Permanent prostate brachytherapy Sector analysis EPIC DNA damage biomarkers (γH2AX and 53BP1) |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c460t-f7e74175418cd58f522d2983ff5f984e43825588d39512fb832794bb1a01b563 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348795/ |
PMID | 28288658 |
PQID | 1884835253 |
PQPubID | 55355 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5348795 proquest_miscellaneous_1891859185 proquest_miscellaneous_1877525953 proquest_journals_1884835253 crossref_primary_10_1186_s13014_017_0792_1 pubmed_primary_28288658 |
PublicationCentury | 2000 |
PublicationDate | 2017-03-14 |
PublicationDateYYYYMMDD | 2017-03-14 |
PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-14 day: 14 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Radiation oncology (London, England) |
PublicationTitleAlternate | Radiat Oncol |
PublicationYear | 2017 |
Publisher | BioMed Central |
Publisher_xml | – name: BioMed Central |
References | S Grudzenski (792_CR14) 2010; 10 S Zahnreich (792_CR8) 2015; 183 EP Rogakou (792_CR10) 1998; 273 AV D’Amico (792_CR3) 1998; 280 MJ Rivard (792_CR21) 2004; 31 792_CR11 G Multhoff (792_CR34) 2012; 2 L Potters (792_CR5) 2005; 173 K Rothkamm (792_CR16) 2007; 242 C Thomas (792_CR36) 2008; 72 M Pinkawa (792_CR18) 2006; 64 U Eberlein (792_CR29) 2015; 42 AB Mohamed Yoosuf (792_CR25) 2015; 14 JL Gowans (792_CR32) 1996; 17 BGL Vanneste (792_CR41) 2015; 114 F Zwicker (792_CR28) 2015; 56 RG Stock (792_CR37) 2002; 41 AB Mohamed Yoosuf (792_CR26) 2013; 12 C Salembier (792_CR22) 2007; 83 JT Wei (792_CR7) 2000; 56 M Lassmann (792_CR12) 2010; 51 F Zwicker (792_CR27) 2011; 6 E Melian (792_CR17) 1997; 38 MG Sanda (792_CR6) 2008; 358 PL Roberson (792_CR24) 1997; 24 R Bender (792_CR42) 2001; 54 L Hathout (792_CR35) 2014; 90 B Oorschot van (792_CR40) 2014; 88 ML Chua (792_CR38) 2011; 99 M Bolla (792_CR2) 2002; 360 WN Andrade (792_CR33) 1998; 91 R Nath (792_CR19) 2009; 36 U Eberlein (792_CR30) 2016; 57 792_CR20 L Klotz (792_CR1) 2015; 33 HV Goutham (792_CR39) 2012; 84 DK Woolf (792_CR9) 2014; 3 A Tejwani (792_CR23) 2012; 4 DC Miller (792_CR4) 2005; 23 R Pabst (792_CR31) 1987; 136 S Horn (792_CR13) 2013; 180 OA Martin (792_CR15) 2013; 12 |
References_xml | – volume: 280 start-page: 969 year: 1998 ident: 792_CR3 publication-title: JAMA doi: 10.1001/jama.280.11.969 contributor: fullname: AV D’Amico – volume: 180 start-page: 603 issue: 6 year: 2013 ident: 792_CR13 publication-title: Radiat Res doi: 10.1667/RR13342.1 contributor: fullname: S Horn – volume: 83 start-page: 3 issue: 1 year: 2007 ident: 792_CR22 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2007.01.014 contributor: fullname: C Salembier – volume: 36 start-page: 5310 issue: 11 year: 2009 ident: 792_CR19 publication-title: Med Phys doi: 10.1118/1.3246613 contributor: fullname: R Nath – volume: 242 start-page: 244 year: 2007 ident: 792_CR16 publication-title: Radiology doi: 10.1148/radiol.2421060171 contributor: fullname: K Rothkamm – ident: 792_CR20 – volume: 72 start-page: 447 year: 2008 ident: 792_CR36 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2007.12.052 contributor: fullname: C Thomas – volume: 88 start-page: 664 issue: 3 year: 2014 ident: 792_CR40 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2013.11.219 contributor: fullname: B Oorschot van – volume: 358 start-page: 1250 issue: 12 year: 2008 ident: 792_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa074311 contributor: fullname: MG Sanda – volume: 31 start-page: 633 issue: 3 year: 2004 ident: 792_CR21 publication-title: Med Phys. doi: 10.1118/1.1646040 contributor: fullname: MJ Rivard – volume: 42 start-page: 1739 issue: 11 year: 2015 ident: 792_CR29 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-015-3083-9 contributor: fullname: U Eberlein – volume: 136 start-page: 1213 year: 1987 ident: 792_CR31 publication-title: Am Rev Respir Dis doi: 10.1164/ajrccm/136.5.1213 contributor: fullname: R Pabst – volume: 12 start-page: 254 year: 2013 ident: 792_CR26 publication-title: Brachytherapy doi: 10.1016/j.brachy.2012.08.007 contributor: fullname: AB Mohamed Yoosuf – volume: 23 start-page: 2772 year: 2005 ident: 792_CR4 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.07.116 contributor: fullname: DC Miller – volume: 91 start-page: 1653 year: 1998 ident: 792_CR33 publication-title: Blood doi: 10.1182/blood.V91.5.1653 contributor: fullname: WN Andrade – volume: 24 start-page: 251 issue: 2 year: 1997 ident: 792_CR24 publication-title: Med Phys doi: 10.1118/1.598058 contributor: fullname: PL Roberson – volume: 56 start-page: 899 year: 2000 ident: 792_CR7 publication-title: Urol doi: 10.1016/S0090-4295(00)00858-X contributor: fullname: JT Wei – volume: 54 start-page: 343 issue: 4 year: 2001 ident: 792_CR42 publication-title: J Clin Epidemiol doi: 10.1016/S0895-4356(00)00314-0 contributor: fullname: R Bender – volume: 2 start-page: 58 year: 2012 ident: 792_CR34 publication-title: Oncol doi: 10.3389/fonc.2012.00058 contributor: fullname: G Multhoff – volume: 12 start-page: 844 issue: 10 year: 2013 ident: 792_CR15 publication-title: DNA Repair (Amst) doi: 10.1016/j.dnarep.2013.07.002 contributor: fullname: OA Martin – volume: 173 start-page: 1562 year: 2005 ident: 792_CR5 publication-title: J Urol doi: 10.1097/01.ju.0000154633.73092.8e contributor: fullname: L Potters – volume: 14 start-page: 703 issue: 5 year: 2015 ident: 792_CR25 publication-title: Brachytherapy doi: 10.1016/j.brachy.2015.05.009 contributor: fullname: AB Mohamed Yoosuf – ident: 792_CR11 doi: 10.1371/journal.pone.0025113 – volume: 17 start-page: 288 year: 1996 ident: 792_CR32 publication-title: Immunol Today doi: 10.1016/0167-5699(96)80547-0 contributor: fullname: JL Gowans – volume: 360 start-page: 103 year: 2002 ident: 792_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(02)09408-4 contributor: fullname: M Bolla – volume: 33 start-page: 272 issue: 3 year: 2015 ident: 792_CR1 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.1192 contributor: fullname: L Klotz – volume: 3 start-page: 329 year: 2014 ident: 792_CR9 publication-title: Springerplus doi: 10.1186/2193-1801-3-329 contributor: fullname: DK Woolf – volume: 273 start-page: 5858 year: 1998 ident: 792_CR10 publication-title: J Biol Chem doi: 10.1074/jbc.273.10.5858 contributor: fullname: EP Rogakou – volume: 57 start-page: 173 issue: 2 year: 2016 ident: 792_CR30 publication-title: J Nucl Med doi: 10.2967/jnumed.115.164814 contributor: fullname: U Eberlein – volume: 4 start-page: 75 year: 2012 ident: 792_CR23 publication-title: J Contemp Brachytherapy doi: 10.5114/jcb.2012.29363 contributor: fullname: A Tejwani – volume: 41 start-page: 434 year: 2002 ident: 792_CR37 publication-title: Eur Urol doi: 10.1016/S0302-2838(02)00018-0 contributor: fullname: RG Stock – volume: 90 start-page: 312 year: 2014 ident: 792_CR35 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2014.06.031 contributor: fullname: L Hathout – volume: 84 start-page: e607 issue: 5 year: 2012 ident: 792_CR39 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2012.06.041 contributor: fullname: HV Goutham – volume: 99 start-page: 362 issue: 3 year: 2011 ident: 792_CR38 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2011.05.071 contributor: fullname: ML Chua – volume: 114 start-page: 276 issue: 2 year: 2015 ident: 792_CR41 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2015.01.005 contributor: fullname: BGL Vanneste – volume: 10 start-page: 14205 issue: 32 year: 2010 ident: 792_CR14 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1002213107 contributor: fullname: S Grudzenski – volume: 38 start-page: 73 year: 1997 ident: 792_CR17 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(97)00221-6 contributor: fullname: E Melian – volume: 56 start-page: 239 issue: 2 year: 2015 ident: 792_CR28 publication-title: J Radiat Res doi: 10.1093/jrr/rru096 contributor: fullname: F Zwicker – volume: 51 start-page: 1318 year: 2010 ident: 792_CR12 publication-title: J Nucl Med doi: 10.2967/jnumed.109.071357 contributor: fullname: M Lassmann – volume: 183 start-page: 432 year: 2015 ident: 792_CR8 publication-title: Radiat Res doi: 10.1667/RR13911.1 contributor: fullname: S Zahnreich – volume: 64 start-page: 856 year: 2006 ident: 792_CR18 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2005.08.016 contributor: fullname: M Pinkawa – volume: 6 start-page: 62 year: 2011 ident: 792_CR27 publication-title: Radiat Oncol doi: 10.1186/1748-717X-6-62 contributor: fullname: F Zwicker |
SSID | ssj0045309 |
Score | 2.1823843 |
Snippet | Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As... Background Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent... BACKGROUNDLow-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 53 |
SubjectTerms | Acute toxicity Aged Antibodies Biomarkers Biomarkers - blood Brachytherapy DNA damage Dosimetry Follow-Up Studies Health risks Histones - blood Humans Immunofluorescence Intestine Lymphocytes Male Middle Aged Neoplasm Grading Prognosis Prospective Studies Prostate cancer Prostatic Neoplasms - blood Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Quality of Life Radiation therapy Radiotherapy Dosage Rectum Survival Rate Toxicity Tumor Suppressor p53-Binding Protein 1 - blood Urinary bladder |
SummonAdditionalLinks | – databaseName: Health & Medical Collection (Proquest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9UwEB_WFcSL-G11lQiehPCaJmmmeBARl4egeFjh3UrzxS5Iu_te97D_vZm0ffoU9pwJhJnJ5DeZL4B32Fm0WhnuZIhcSe84hs7wqpPGWacw2QfKtvher3-qrxu9OYL1UgtDaZWLTcyG2g-O_shXAlERWtBy1Vn6BXDj6uPlFaf5URRnnYdp3IG7okqwImm22exdL6Vl2cwxTYH1aifIk-BkoUvTVFwcvkr_Qc1_Myb_eoJOH8KDGTuyT5OwH8FR6B_DvW9zdPwJXP2gEo4EHpkjWW5ZziIPntFnK0tusTu_meqtbj6wrmch59_lMDvLbWbZEJkfdoEvo3FHRuX5lMGz3aUdnk01mJnw10UMT-Hs9MvZ5zWfRypwp-py5NGEBCGMVgKd1xgT-vJVgzJGHRtUgcKCWiN6mZBXFW267-nCWiu6Ulhdy2dw3A99eAGsssGLEGiyRFTCYyNicqZjWaOPulOygPcLR9vLqXFGmx0OrNuJ_W1if0vsb0UBJwvP2_kO7do_Ei_g7X45aT-FNLo-DNdEY0yiaG6naQR16UNdwPNJjPsTkcOJCYQVYA4EvCeg7tuHK_3Fee7CraWiQe0vbz_6K7hfZTWTXKgTOB631-F1gjGjfZM19DdvHPUk priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access(OpenAccess) dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxwxEA-iUHwRP2o9ayWCT4XUzSbZzFJEilSkYPFBwbdls0lQkD29O6H333cmu3tolT74vJNlyW8m-c3OF2OHUDtwRlvRqBCFVr4REGor8lrZxjUa8HygbIvfxfm1_nVjbpbYMN6q38Dpm64dzZO6ntx_-_M4P0GDP04GD8XRVJJfIOi8zWyZC3SGVnKtNCn8hV4EFbRRWdkHNt9cRo2B0QGBgua_P7-lXlHPfzMon11JZ-tsreeS_EcH_gZbCu0m-3DRR8u32OMllXQgmeQNYTvhKas8eE4_Xzm6yc3tvKu_mn_ndctDysdLYXee2s7yceR-PA1iGJU741SuTxk9kymu8LyryUyC93cxfGRXZz-vTs9FP2JBNLrIZiLagJTCGi2h8QYisjGfl6BiNLEEHShMaAyAV8jE8ujQ_tGAnZN1Jp0p1DZbbsdt2GE8d8HLEGjSRNTSQykjOtcxK8BHU2s1Yl-HHa0eukYaVXJAoKg6JCpEoiIkKjlie8OeV4NKVBJAE180-K6DxWO0Bgpx1G0YP5GMtShR_l-mlNS1D8yIfepgXHzRgP-I2RcALwSoG_fLJ-3dberKbZSmwe277175ma3mSRmVkHqPLc8mT-ELMp6Z2096_BdyaQHS priority: 102 providerName: Scholars Portal |
Title | Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28288658 https://www.proquest.com/docview/1884835253/abstract/ https://search.proquest.com/docview/1877525953 https://search.proquest.com/docview/1891859185 https://pubmed.ncbi.nlm.nih.gov/PMC5348795 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtB2MvY91Xs3VBgz0N1FiWZJ3pU1paSiAlbB3kzVhfNNA6XZI-9L-fTrZDu0Ef9mI_6GyM7yT9Tve7O0K-QW3AKKmZFT4wKZxl4GvN8lpoa6yEuD4g2-KyuPglJ3M13yGqz4VJpH1rFkfNze1Rs7hO3Mq7WzvqeWKj2fRUCYk9ske7ZFcL0bvo7fIrlcjKLnzJoRitOToNDBfjTJc5w9Yw6GZAgV3eH-9F_wDMv3mSjzae8zfkdYcY6bj9sn2y45u35OW0i4m_I79nmLgRISO1qMEVTdxx7ygesdLoDNvrhzbL6uGY1g31iXWXgus0FZely0Ddcu1Z3xB3QzEpH3k7q3V8wtE28zIJ3iyCf0-uzs-uTi9Y10iBWVlkGxa0j8BBK8nBOgUhYi6XlyBCUKEE6TEYqBSAExFv5cHEWR6nqTG8zrhRhfhA9ppl4w8IzY133HvsJxEkd1DyEF3okBXggqqlGJDv_R-t7tpyGVVyM6CoWk1UURMVaqLiA3LY__OqmznrigNIRIUqvuvrdjjaPAYy6sYv71FG6yhRPi9TcqzNB2pAPrZq3H5Rr_8B0U8UvBXAmttPR6Ipptrbnel9-u8nP5NXeTJGwbg8JHub1b3_EnHNxgyjNc_1kLwYjyc_J_F-cnY5-zFMpwTxOpUwTJb-BwSPAGU |
link.rule.ids | 230,315,733,786,790,870,891,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEB-0gvoifrva1gg-CaGbTbLJ4oNIaTm1LT6ccG9h80ULZbe9vT70vzeT3Ts9hT7vLISZZPKbzG9mAD7q1morhaKOh0gF947q0CpatVw564RO_gHZFmf17Jf4vpCL6cFtmGiVa5-YHbXvHb6RHzCtBaIFyb9cXVOcGoXZ1WmExn14IDgXSOlTi03AJSQvmymTyXR9MDCMHyj65VI1FWXbd9F_APNfnuRfF8_xU3gyIUbydTTxM7gXuufw8HTKib-A659YuJEgI3FowSXJ3PHgCT6xkhQMu_Pbscrq9jNpOxIy6y4n10luLkv6SHw_BLoeiLsiWJSPvJ3lkP7wZKy8zIKXFzG8hPnx0fxwRqdBCtSJulzRqEICDkoKpp2XOibM5atG8xhlbLQImAyUUmvPE96qok2nPB1Ta1lbMitr_gp2ur4Lb4BUNngWAs6TiIJ53bCYQuhY1tpH2QpewKe1Rs3V2C7D5DBD12ZUv0nqN6h-wwrYXevcTCdnMH_sXMCHzee05zGR0Xahv0EZpZJEc7dMw7A3n5YFvB7NuFkRhpk6Qa8C1JaBNwLYc3v7S3dxnntvSy5wPPvbu5f-Hh7N5qcn5uTb2Y938LjKW45TJnZhZ7W8CXsJyKzsft6tvwFvgPRX |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUX3o8tBYzECcmbOLZjR5xQYVUerfZQpIqLFb_UFW12u5s9lF-Px0lW2yJx6NmTyNGMx99kvplB6L2qjTKCS2KZD4QzZ4nytSRFzaQ1lqvoH4BtcVwe_uTfTsXp1qivRNq3ZjZuzi_GzewscSsXFzYbeGLZ9OhAMA4zsrOFC9lddC-e2aIaAvXOCXPB8qpPYlJVZisKoQMBl5zLqiAwIAaCDVXCrPftG-kfmHmTLbl1_Uweol_DxjvWye_xujVj--dGT8dbfdkj9KAHpfhTJ_IY3fHNE7R71Kfdn6LLKdSGRFSKLRjJEid6uncY_uLiGG_bs6uukOvqI64b7BOxL-Xvcepfi-cBu_nKk2Hmbouh7h-oQctVfMLhrrgzCZ7Pgn-GTiZfTg4OST-rgVhe5i0J0kdsIgWnyjqhQoR1rqgUC0GESnEP-UYhlHIsQroimOhIoicwhtY5NaJkz9FOM2_8S4QL4x31HkZWBE6dqmiIUXrIS-WCqDkboQ-DuvSi68ihUySjSt2pWUc1a1CzpiO0PyhU94dzpalSHICniO96t1mOxwpyJXXj52uQkTJKVP-XqSi0_1NihF50NrLZ0WBcIySvWc9GANp6X1-JNpHae_c2sHfrJ9-i3ennif7x9fj7K3S_SEbPCOX7aKddrv3riKJa8yadl78X_B8K |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostate+cancer+treated+with+brachytherapy%3B+an+exploratory+study+of+dose-dependent+biomarkers+and+quality+of+life&rft.jtitle=Radiation+oncology+%28London%2C+England%29&rft.au=Osman%2C+Sarah+O.+S.&rft.au=Horn%2C+Simon&rft.au=Brady%2C+Darren&rft.au=McMahon%2C+Stephen+J.&rft.date=2017-03-14&rft.pub=BioMed+Central&rft.eissn=1748-717X&rft.volume=12&rft_id=info:doi/10.1186%2Fs13014-017-0792-1&rft_id=info%3Apmid%2F28288658&rft.externalDBID=PMC5348795 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1748-717X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1748-717X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1748-717X&client=summon |